Lantern Pharma Inc.
LTRN · NASDAQ
Market closed$2.87$-0.040000 (-1.37%)After hours $2.87 · 0.00%
Key statistics
Previous close$2.91
Open$2.82
Day high$3.05
Day low$2.82
52-week high$5.74
52-week low$1.11
Market cap36.62M
Volume105.16K
Average volume242.13K
P/E ratio-1.98
Forward P/E—
EPS-1.45
Dividend yield0.00%
Market context
Why it moved
LTRN edged lower amid light volume and a lack of company-specific catalysts, reflecting broad selling pressure and general market weakness in small-cap stocks.
What is happening
Recent company-specific developments and publisher coverage.
Stock Titan · June 12, 2026Lantern Pharma (NASDAQ: LTRN) files S-1 resale and flags funding riskStock Titan · May 19, 2026FDA lets lung cancer trial focus on never-smokers with EGFR exon 21 L858RBusiness Wire · May 15, 2026Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business UpdatesBusiness Wire · May 14, 2026Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional InvestorInvesting.com · May 13, 2026Lantern Pharma raises $4.4M in registered direct offeringBusiness Wire · May 13, 2026Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional InvestorBusiness Wire · April 24, 2026Lantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific DebutClinical Trials Arena · March 30, 2026Lantern receives FDA clearance for paediatric STAR-001 CNS trial Benzinga · July 8, 2026Lantern Pharma Launches ZetaOmics, A Computational-Biology Module Of Its WithZeta.ai Co-Scientist Platform Benzinga · June 12, 2026Lantern Pharma Announces Selling Stockholders May Sell Up To 2.24M Shares Of Common Stock Mt Newswire · June 2, 2026Lantern Pharma Says Longer LP-300 Treatment Helped Lung Cancer Patients in Phase 2 Study Benzinga · June 2, 2026Lantern Pharma Reports Clinical Data And Updates From Ongoing Phase 2 HARMONIC Trial Evaluating LP-300 In Combination With Carboplatin And Pemetrexed In Patients With EGFR Exon 21 L858R-Mutant NSCLC Benzinga · May 19, 2026Lantern Pharma Receives Successful Response To Its Recent FDA Type C Meeting Request Focused On The Ongoing Phase 2 HARMONIC Trial Of LP-300 In Never-Smokers With Advanced Non-Small Cell Lung Cancer Adenocarcinoma Benzinga · May 15, 2026Lantern Pharma Q1 EPS $(0.30) Beats $(0.36) Estimate Benzinga · May 13, 2026Lantern Pharma Announces Up To $9.25M Direct Offering With Existing Shareholders And Unnamed Institutional Investor; Transaction Expected To Close May 14 Benzinga · April 29, 2026Lantern Pharma Expands Its predictBBB.ai Web Service Into A Large Quantitative Model